 Connection
Scott Kono to Prognosis
This is a "connection" page, showing publications Scott Kono has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.040 |
|
|
|
-
Ramalingam SS, Owonikoko TK, Behera M, Subramanian J, Saba NF, Kono SA, Gal AA, Sica G, Harvey RD, Chen Z, Klass CM, Shin DM, Fu H, Sun SY, Govindan R, Khuri FR. Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):369-72.
Score: 0.014
-
Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, M?ller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, Chen Z, Shin HJ, Grandis JR, Khuri FR, Chen ZG. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res. 2013 Mar 01; 19(5):1244-56.
Score: 0.014
-
Camidge DR, Kono SA, Lu X, Okuyama S, Bar?n AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W, Doebele RC. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011 Apr; 6(4):774-80.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|